YnnoMed Limited, a PolyU startup co-founded by Dr Ma Cong, Associate Professor of the Department of Applied Biology and Chemical Technology, is set to make its mark at the highly anticipated BIO International Convention 2024 (BIO 2024) in California next week. As the world's largest and most comprehensive event for biotechnology, the convention provides an ideal platform for YnnoMed to unveil its groundbreaking drug candidates.
The drug R&D startup has successfully developed a new class of antibiotic agents and obtained patents in several key regions, including the United States, mainland China, Europe, and Japan. Dr Ma said they target to obtain Food and Drug Administration accreditation for the new product, and to commence clinical trials in 2026.
With its potential to revolutionize the field of antibiotic treatments, YnnoMed is poised to make waves at this prestigious event and shape the future of biotechnology.
